Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-145-4 | CAS number: 78-81-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics, other
- Remarks:
- Assessment of the toxicokinetic behaviour of isobutylamine to the extent that can be derived from relevant available information
- Type of information:
- other: Supporting Document for Submission
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Justification for type of information:
- According to Annex VIII REACH: Assessment of the toxicokinetic behaviour to the extent that can be derived from relevant available information.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
- Report date:
- 2018
Materials and methods
- Objective of study:
- absorption
- distribution
- excretion
- metabolism
- toxicokinetics
- GLP compliance:
- no
Results and discussion
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Iso-butylamine is polar in it’s nature (as indicated by a Log Kow of 0.73 with an aqueous solubility of 1000 mg/mL at 25°C) and low molecular weight (73.1 g/mol) and is, therefore, expected to be readily absorbed through the skin, the respiratory tract via inhalation and across the gastro-intestinal tract.
For the animals dosed iso-butylamine via oral gavage administration, clinical signs of centrally mediated effects of central nervous system (CNS) depression were reported, indicating systemic exposure to iso-butylamine. At the higher doses, convulsions and death were observed, providing evience of a dose related increase in absorption across the GI tract. Time to the death for male rats dosed with iso-butyamine and iso-propylamine ranged between 1-3 hours and 7 minutes-4 hours, respectively, suggesting oral absorption was rapid.
Absorption into the systemic circulation via the lungs has been demonstrated in the 90 day repeat dose and developmental toxicity studies where the animals were exposed to a vapour of iso-propylamine and where treatment related clinical signs including changes in body weight and clinical chemistry (mild) were observed.
In the acute dermal toxicity studies with butylamine and iso-propylamine, treatment related findings such as dyspnoea, apathy, staggering, spastic gait, tremor, piloerection, exophthalmos, poor general state and death, provides evidence of absorption into the systemic circulation via the skin. For the animals exposed to iso-propylamine, the systemic effects were observed on the day of application, suggesting absorption through the skin was rapid.
Following the “read-across” approach to iso-propylamine, it would be reasonable to assume that absorption into the systemic circulation via the lungs or the skin would also be routes of absorption for iso-butylamine - Details on distribution in tissues:
- Due to the physico-chemical properties described for iso-butylamine, the substance would be expected to distribute into tissues. Confirmation of distribution into tissues following oral administration (iso-butylamine), inhalation and dermal exposure (iso-propylamine) was indicated by the clinical observations observed during the toxicity studies, suggestive of centrally mediated effects indicating penetration into the brain, and CNS. The times (1-3 hours) to the first mortalities of the animals in the acute oral toxicity study (Section 3.1) demostrates that distribution to the tissues following oral administration is likely to be rapid. Therefore, based on the “read-across” approach it would not be unreasonable to assume a rapid and general distribution of iso-butylamine into highly perfused tissues throughout the body.
- Details on excretion:
- Excretion studies have not been cited in the literature for iso-buylamine or the structurally similar amines iso-propylamine and butylamine.
Since iso-butylamine is a highly polar molecule with low molecular weight (73.1 g/mol), the major route of exretion for iso-butylamine and metabolites is likley to be via the kidneys, significant excretion in bile would not be expected. It is also reasonable to assume that phase 2 metabolism (i.e. conjugation) would not play a major role in the elimination of iso-butylamine or it’s metabolites.
Metabolite characterisation studies
- Details on metabolites:
- Metabolism studies have not been cited in the literature for iso-buylamine or the structurally similar amines iso-propylamine and butylamine. Therefore, based on the structure of iso-butylamine and following absorption through the GI tract wall to the liver, metabolism would likely proceed via phase 1 metabolism, mediated by cytochrome P450s, monooxygenases and flavine monooxygenases. The biotransformation9,10 of iso-butylamine in is likely to proceed by 3 concurrent pathways; hydroxylation of the aliphatic carbons to iso-butylhydroxylamine (preferencial on the secondary or tertiary sites), N-oxidation to N-isobutylhydroxylamine and oxidative deamination, forming the corresponding aldehyde and ammonia. The aldehyde would further metabolise via hydrolysis to the corresponding carboxylic acid and the ammonia would be available as a substrate for urea synthesis in the liver.
Since iso-butylamine is a highly polar molecule with low molecular weight (73.1 g/mol), the major route of exretion for iso-butylamine and metabolites is likley to be via the kidneys, significant excretion in bile would not be expected. It is also reasonable to assume that phase 2 metabolism (i.e. conjugation) would not play a major role in the elimination of iso-butylamine or it’s metabolites.
Applicant's summary and conclusion
- Conclusions:
- Iso-butylamine would be rapidly absorbed following oral and dermal administration and the same would be expected following exposure via inhalation. Once absorbed into the systemic circulation a general and rapid distribution of iso-butylamine into highly perfused tissues throughout the body would be expected as indicated by clinical observations suggestive of penetration into the brain, CNS and lungs. The biotransformation of iso-butylamine is likely to proceed via 3 concurrent pathways: hydroxylation of the aliphatic carbons, N-oxidation and oxidative deamination. Since iso-butylamine is a higly polar molecule with low molecular weight the major route of exretion for iso-butylamine and metabolites is likelyto be via the kidneys, significant excretion in bile would not be expected. It is also reasonable to assume that phase 2 metabolism (i.e. conjugation) would be unlikely to play a major role in the elimination of iso-butylamine or it’s metabolites.
- Executive summary:
According to Annex VIII REACH an assessment of the toxicokinetic behaviour of isobutylamine was performed to the extent that can be derived from relevant available information.
An assessment of the toxicokinetics of iso-butylamine was undertaken to obtain a consensus on the in vivo toxicokinetic behaviour of the aliphatic amine in terms of its absorption, distribution, metabolism and excretion. This assessment was made on the basis of physical chemical properties and relevant data in the scientific literature. Data generated in a number of iso-propylamine and butylamine toxicity studies will be used to “read-across” to iso-butylamine.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.